PolyPid Ltd. (PYPD) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Quote Panel

Updated July 2, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

Relative Strength

PYPD

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-3.90
vs -18.32

Q3.23

N/A

-3.40
vs -14.41

Q4.23

N/A

-3.97
vs -9.61

Q1.24

N/A

-1.37
vs -8.41

Q2.24

N/A

-1.25
vs -3.90

Q3.24

N/A

-1.22
vs -3.40

Q4.24

N/A

NA
vs -3.97

Q1.25

N/A

-0.70
vs -1.37

Q2.25

N/A

-0.55
vs -1.25

Q3.25

N/A

-0.33
vs -1.22

Sales Growth

YoY

Current

Estimates

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Q4.24

NA

NA vs NA

Q1.25

NA

NA vs NA

Return on Equity

QoQ

Q2.23

-70%

-0.70
vs -0.53

Q3.23

-158%

-1.58
vs -0.70

Q4.23

+303%

3.03
vs -1.58

Q1.24

-90%

-0.90
vs 3.03

Q2.24

-393%

-3.93
vs -0.90

Q3.24

-360%

-3.60
vs -3.93

Q4.24

-111%

-1.11
vs -3.60

Q1.25

-9614%

-96.14
vs -1.11

Institutionnal Ownership

QoQ

Q3.21

19

19
vs 22

-14%

Q4.21

30

30
vs 19

58%

Q1.22

31

31
vs 30

3%

Q2.22

30

30
vs 31

-3%

Q3.22

21

21
vs 30

-30%

Q4.22

14

14
vs 21

-33%

Q1.23

10

10
vs 14

-29%

Q2.23

13

13
vs 10

30%

Earnings Growth

Latest News

PYPD

globenewswire.com

7 hours ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PYPD

globenewswire.com

8 hours ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PYPD

globenewswire.com

9 hours ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PYPD

globenewswire.com

9 hours ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PYPD

globenewswire.com

16 hours ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PYPD

globenewswire.com

19 hours ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results